Cargando…
Long-term safety and tolerability of donepezil 23 mg in patients with moderate to severe Alzheimer’s disease
BACKGROUND: Donepezil (23 mg/day) is approved by the US Food and Drug Administration for the treatment of patients with moderate to severe Alzheimer’s disease (AD). Approval was based on results from a 24-week, randomized, double-blind study of patients who were stable on donepezil 10 mg/day and ran...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3493328/ https://www.ncbi.nlm.nih.gov/pubmed/22681723 http://dx.doi.org/10.1186/1756-0500-5-283 |